Yixintang Pharmaceutical Group (002727.SZ) Earnings Analysis
Yixintang Pharmaceutical Group (002727.SZ) next reports earnings on 2026-08-27, consensus EPS 0.2254 CNY. Last quarter (2025-10-30) it missed with EPS 0.03299 CNY vs 0.285 CNY est (-88.4%). It has beaten estimates in 0/3 recent quarters (0%). Trailing P/E 23.40.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 002727.SZ next report earnings?
| Next earnings date | 2026-08-27 |
|---|---|
| Consensus EPS estimate | 0.2254 CNY |
| Revenue estimate | 4.19B |
002727.SZ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-10-30 | 0.03299 CNY | 0.285 CNY | -88.4% | Miss |
| 2025-06-30 | 0.1529 CNY | n/a | n/a | n/a |
| 2025-04-27 | 0.27 CNY | 0.35 CNY | -22.9% | Miss |
| 2025-03-31 | 0.2733 CNY | n/a | n/a | n/a |
| 2024-08-30 | 0.07 CNY | 0.22 CNY | -68.2% | Miss |
Beat rate: 0/3 (0%) over reported quarters with consensus data.
002727.SZ valuation and analyst view
| Trailing P/E | 23.40 |
|---|---|
| Trailing EPS | 0.48625 CNY |
| Price / book | 0.87 |
| Dividend yield | 3.54% |
| Market cap | 6.66B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Yixintang Pharmaceutical Group (002727.SZ)'s next earnings date?
Yixintang Pharmaceutical Group is next scheduled to report on 2026-08-27, with a consensus EPS estimate of 0.2254 CNY and revenue estimate of 4.19B.
Did 002727.SZ beat earnings last quarter?
In its 2025-10-30 report, 002727.SZ posted EPS of 0.03299 CNY versus a 0.285 CNY estimate — a miss of 88.4%.
What is 002727.SZ's earnings track record?
Over the last 3 reported quarters with consensus data, 002727.SZ beat estimates 0 times (0%).
What is 002727.SZ's current P/E ratio and EPS?
002727.SZ trades at a trailing P/E of 23.40 on trailing EPS of 0.48625066639077014 CNY.
What do analysts rate 002727.SZ?
002727.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.